

# Yorkshire Cancer Network

## Skin Cancer Group

Minutes of the meeting held on  
**Tuesday 12<sup>th</sup> October 2004, 2.00pm**  
YCRN Conference Suite, Ida Nurses Home, Cookridge Hospital

---

Present:	Dr J O'Dowd	Airedale NHS Trust
	Dr A Wright	Bradford Teaching Hospitals NHS Trust
	Ms J Smith Dr M Cheesbrough Dr J Holder	Calderdale & Huddersfield NHS Trust
	Ms D Beirne Dr A Boon Ms M Cronk Dr W Merchant (Chair) Professor J Newton Bishop Dr G Stables	Leeds Teaching Hospitals NHS Trust
	Dr C Lyon	York Hospitals NHS Trust
	Mr P Melling Mrs H Ryan	Yorkshire Cancer Network

### 1. Apologies for absence

Professor M Baker, Dr Barbar, Dr H Galvin, Dr F Hicks, Mr H Peach, Ms C Sleigh, Mr MJ Timmons, Mr B Tinkler and Ms C Wheelhouse.

### 2. Minutes from the last meeting

Were agreed as being an accurate record.

### 3. Matters arising

- **BCC/SCC Minimum Dataset**

Dr Merchant tabled a Basal Cell Carcinoma Minimum Cancer Dataset feedback form for completion by clinicians prospectively to encourage Minimum Data Set collection. St James's University Hospital and Leeds General Infirmary would pilot the form initially. A discussion followed.

Dr Merchant informed the group that he received a letter inviting all 34 skin Cancer Network Leads to a meeting with Professor Mike Richards in December to discuss how the National Team can support Skin Cancer Leads to take forward the skin cancer agenda. The group agreed to ask for clarity on where the Network should be in terms of the Minimum Dataset at this meeting.

- **SCC Audit Progress Report**

Dr Stables highlighted that the SCC Audit Report will be presented at the Regional Dermatology meeting on Friday 5<sup>th</sup> November.

**Actions: Mrs Ryan to circulate handouts to the group following the meeting.**

- **Primary Care Representative**

Dr Potts was not present at the meeting to update the group.

**Action: Dr Merchant to write to Dr Potts for an update.**

#### **4. Cancer Peer Review**

Dr Merchant updated the group on the Yorkshire Cancer Network Quality Measures for Cancer Peer Review document which was produced in July 2004.

It was noted that Skin Cancer would not be reviewed in phase I of Peer Review. Dr Merchant highlighted that group could opt to be in the Peer Review programme using the generic MDT Quality Measures in anticipation of phase II. These generic measures will be examined to gain understanding of the process.

Dr Lyon confirmed that York is carrying out a self assessment against the Quality Measures for skin cancer.

Mr Melling highlighted that the YCN is being reviewed in September and October 2005.

A discussion followed regarding the frequency and attendance at MDT's. In particular lack of funding to support the Melanoma MDT.

#### **5. Yorkshire Skin Lymphoma Guidelines**

Professor Newton-Bishop informed the group that a regional meeting took place to discuss guidelines for cutaneous lymphoma management. The meeting was attended by dermatologists, pathologists, haematologists and the Cookridge lymphoma team.

The guidelines are progressing and are currently with Dr D Gilson and Dr R Taylor who are completing the chemotherapy sections.

Professor Newton-Bishop explained that the guidelines are a way of producing uniformity of care across the Network and more cohesion between the clinical oncologists and dermatologists in the absence of a skin cancer lead at Cookridge

A discussion followed regarding development of the guidelines. It was agreed that two consultant sessions would be required, to include the Humber and Yorkshire Coast Cancer Network and to apply for funding through Professor M Baker at the Yorkshire Cancer Network.

**Action: Mrs Ryan to email guidelines to group once they have been agreed for discussion at the next meeting.**

**Dr Merchant to put Business Case to Professor Baker to support dermatologist with special interest in skin lymphoma.**

#### **6. Clinical Trials Update**

Ms Cronk tabled a paper regarding Melanoma Trials for September 2004.

Ms Beirne highlighted that the Leeds database (PPM) will now record the unit the patient has been referred from and by which clinician. This will help to enable better trial feedback.

#### **7. Staging/ Prognostic Information**

A letter from Dr Mike Leahy, Chair of YCN Information Group was circulated with the agenda.

Professor Newton Bishop explained that currently the AJCC revised staging system is used for melanomas.

Mr Melling highlighted that the letter encourages Network Groups to consider ways to improve the recording of staging information in a way that the Cancer Registry can pick up, for example in case notes or MDT records and to ask groups if there were other prognostic indicators which Network Groups would be interested in developing.

Mr Melling explained that the pathology MDS forms would address this issue.

A discussion followed on recording of staging at the MDT.

Mr Melling highlighted that the way that NYCRIS collects data will change. Currently people from NYCRIS examine the patients' records 6 months after notification. In the future each Trust will be responsible for sending the Registry dataset to NYCRIS which has implications for the Network dataset.

## **8. Cancer Waiting Times**

Mr Melling tabled Skin Cancer Waiting Times data for date of urgent referral to date of first seen (21 days), date of decision to treat to date of treatment (31 days) and date of urgent referral to date of treatment (62 days) for the last quarter of 2003/04 and the first quarter of 2004/05. Mr Melling explained the data to the group.

It was confirmed the cancer waiting times for skin cancer includes melanomas and the first squamous cell carcinoma.

A discussion followed regarding the definition of decision to treat to treatment. Professor Newton-Bishop highlighted that this issue has been discussed at the NICE Skin Cancer Guidelines Committee without resolution. The issue is whether treatment should be defined as the removal of the lesion or wider local excision.

The group agreed to continue with local definitions until there is National Guidance, which is expected in April 2005.

## **9. Any Other Business**

### **• YCN Skin Cancer Pathology Guidelines**

Dr O'Dowd tabled the draft YCN Skin Cancer Pathology Guidelines produced by the Chair of the YCN Pathology Group.

**Action: All to send comments to Mrs Ryan.**

### **• NICE Guidance**

The group discussed the management of skin cancer teams by PCT's with a lead appointed by the PCT. The problem of PCTs and separate hospital Trusts leading to a two-tier system was raised. In particular PCT should be integrated with the hospital service. This would benefit education, supervision and consistency.

**Action: Dr Wright to forward a description of the PCT experience at Bradford to Professor Newton-Bishop and copy to the group.  
Professor Newton-Bishop to forward comments to NICE.**

### **• COHORT Study**

Professor Newton Bishop highlighted that 724 patients have been recruited into the COHORT study and thanked all for their support.

- **Business Plan**

Professor Newton-Bishop highlighted that she and Mr Peach have written a Business Plan for the development of a Melanoma Specialist. The business case will go to Professor Baker for approval.

#### **10. Date of 2005 Meetings**

<b>Date</b>	<b>Time</b>	<b>Venue</b>
Tuesday 22 <sup>nd</sup> February 2005	2.00pm	Arthington House Conference Suite, Cookridge Hospital
Wednesday 22 <sup>nd</sup> June 2005	2.00pm	Arthington House Conference Suite, Cookridge Hospital
Tuesday 18 <sup>th</sup> October 2005	2.00pm	Arthington House Conference Suite, Cookridge Hospital